Acute Myeloid Leukemia (AML) is more than a diagnosis. It is a serious form of leukemia characterized by fast progression of cancerous changes in the blood system that affects the production of healthy blood cells. Due to the malfunction of immature cells and their rapid growth, they crowd the healthy cells. With such diseases, targeted drugs like Enasidenib have become a major mode of therapy, especially for patients with IDH2mutations.
What Is an IDH2 Mutation?
However, for certain people suffering from AML, the initial root cause is genetic. The IDH2 mutation is the mutation that occurs in a gene, influencing blood cell formation. As a result of this gene mutation, the development of the cells will not lead to the production of healthy and mature blood cells. They remain immature and accumulate in the body, leading to leukemia.
What Is Enasidenib?
It is therefore a step forward from conventional chemotherapy to targeted medicine. The medication is an oral treatment which is designed to specifically treat individuals with acute myeloid leukemia who have an IDH2 mutation. Instead of targeting all fast-growing cells, Enasidenib targets the metabolic disorder caused by the mutation.
How Does The Medicine Support AML Patients?
The mutated form of IDH2 enzyme creates a toxic substance that prevents cell maturation. The tablet helps in inhibiting this enzyme and decreasing its toxic product so that immature cells can mature normally. It does not kill cells; rather, it helps them normally develop, which is a novel way to combat the problem.
What Are The Benefits of The Treatment?
- The medicine targeting the underlying cause for development of AML in case of IDH2 mutation.
- It promotes maturation of immature cells into mature blood cells.
- Oral route of administration makes it convenient as compared to intensive treatment regimens.
- The tablet enhances the quality of life during treatment.
- An alternative for those who cannot tolerate intense chemotherapy.
Which Patients May Benefit from The Tablet?
The medicine is most useful in the following situations:
- Patients suffering from AML with an IDH2 mutation.
- Relapsed and refractory patients of AML.
- Patients who are not fit for intensive chemotherapy.
- Patients looking for alternative mechanisms of treatment.
What Symptoms May Appear While Taking The Medications?
Although the tablet is considered to have fewer side effects compared to some conventional treatment methods, they may include the following:
- Nausea
- Vomiting
- Fatigue
- Diarrhea
- Elevated levels of bilirubin
- Poor appetite
Differentiation syndrome is one such side effect that must be attended to right away.
What Are the Brand Names of Enasidenib?
This medication can be accessed under the following brand names:
The above mentioned medicines contain an active component. These drugs are administered to patients as per their clinical condition.
How The Tablet Interact with Other Medicines?
It may have drug interactions that might affect the effectiveness of the medication or increase side effects.The patient should notify the healthcare practitioner if:
- Medications currently being taken
- Any herbal products being used
- Any OTC drugs being used
Conclusion
The Enasidenib is a breakthrough therapy in the treatment of Blood Cancer(Acute Myeloid Leukemia). It works well especially on patients with IDH2 mutation. Through molecular targeting, it is more effective and convenient than other traditional drugs used. With ongoing studies, such targeted treatments have transformed the face of cancer treatment in the future.
FAQs
1. Is This Targeted Therapy completely treat AML?
It is a medication that helps in treating the disease and improving outcomes; however, it depends on various patient-related factors.
2. Does a patient require monitoring during treatment?
Monitoring through blood tests and other medical examinations is very important to ensure safety.
Read More – Acalabrutinib for Blood Cancers: Understanding Its Role in Modern Targeted Therapy
References
- Short, N. J., Rytting, M. E., & Cortes, J. E. (2018). Acute myeloid leukaemia. The Lancet, 392(10147), 593-606. Https://www.sciencedirect.com/science/article/abs/pii/S0140673618310419
- Pirozzi, C. J., & Yan, H. (2021). The implications of IDH mutations for cancer development and therapy. Nature reviews Clinical oncology, 18(10), 645-661. Https://pubmed.ncbi.nlm.nih.gov/34131315/
- Kim, E. S. (2017). Enasidenib: first global approval. Drugs, 77(15), 1705-1711. Https://adisjournals.figshare.com/articles/online_resource/Enasidenib_First_Global_Approval/6083435
- Stein, E. M. (2017). Enasidenib, a targeted inhibitor of mutant IDH2 proteins for treatment of relapsed or refractory acute myeloid leukemia. Future Oncology, 14(1), 23-40. Https://ashpublications.org/blood/article/130/6/722/36814/Enasidenib-in-mutant-IDH2-relapsed-or-refractory
- Del Principe, M. I., Paterno, G., Palmieri, R., Maurillo, L., Buccisano, F., & Venditti, A. (2019). An evaluation of enasidenib for the treatment of acute myeloid leukemia. Expert Opinion on Pharmacotherapy, 20(16), 1935-1942.https://pubmed.ncbi.nlm.nih.gov/31454277/
